cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Raymond Pranata
Contact Email
raymond_pranata@hotmail.com
Phone
+6282112918892
Journal Mail Official
ijc@inaheart.org
Editorial Address
Editorial Office: Heart House, Jalan Katalia Raya No. 5, Kota Bambu Utara West Jakarta, 11430 - Indonesia Telephone: +62 21 5681149, Fax: +62 21 5684220 Email: ijc@inaheart.org
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Indonesian Journal of Cardiology
Published by Indonesian Heart Association
ISSN : 28303105     EISSN : 29647304     DOI : -
Core Subject : Health,
Health Professions Medicine & Pharmacology
Indonesian Journal of Cardiology (IJC) is a peer-reviewed and open-access journal established by Indonesian Heart Association (IHA)/Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) [www.inaheart.org] on the year 1979. This journal is published to meet the needs of physicians and other health professionals for scientific articles in the cardiovascular field. All articles (research, case report, review article, and others) should be original and has never been published in any magazine/journal. Prior to publication, every manuscript will be subjected to double-blind review by peer-reviewers. We consider articles on all aspects of the cardiovascular system including clinical, translational, epidemiological, and basic studies. Subjects suitable for publication include but are not limited to the following fields: Acute Cardiovascular Care Arrhythmia / Cardiac Electrophysiology Cardiovascular Imaging Cardiovascular Pharmacotherapy Cardiovascular Public Health Policy Cardiovascular Rehabilitation Cardiovascular Research General Cardiology Heart Failure Hypertension Interventional Cardiology Pediatric Cardiology Preventive Cardiology Vascular Medicine
Arjuna Subject : Kedokteran - Cardiology and Cardiovascular Medicine
Articles 712 Documents
 45   46   47   48   49 
Sistem Skor Baru untuk Memprediksi Kejadian Perdarahan pada Pasien Infark Miokard Akut dengan Elevasi Segmen ST yang Dilakukan Intervensi Koroner Perkutan Primer Wisnu A Widodo; Sunarya Soerianata; Andang H Joesoef; Ganesya M Harimurti
Jurnal Kardiologi Indonesia Vol. 34, No. 4 Oktober - Desember 2013
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v34i4.380

Abstract

Background Acute myocardial infarction still become one of the leadingmortality cause in the world. Among these patients, ST elevation myocardialinfartion (STEMI) has the greatest mortality rate among other type ofMyocardial Infarction. When a myocard infarct patient have bleeding events,mortality rate greatly increased. Up until now, there is no specific bleedingrisk assessment tool to predict bleeding events in STEMI patient.Methods A retrospective cohort study, done in National Cardiovascular CenterHarapan Kita, Jakarta in STEMI patients underwent Primary PercutaneousCoronary Intervention (PPCI). Bleeding event was defined according to definitionby Bleeding Academic Research Consortium (BARC) – European Societyof Cardiology, 2011. Categories for data obtained was basic characteristics,clinical examinations, initial therapies, lab results, x-ray, PPCI procedures, andin hospital treatments. Statistical analysis was done using multivariat analysisusing logistic regression method and then converted to a scoring system.Results 579 sampels fit the inclusion and exclusion criteria. Bleeding eventoccured in 42 patients (7.3%). Indonesia bleeding score (Range 1-100) wascreated by assignment of variables that included in the final model accordingto their Odds Ratio (OR) values. Those variables are: female gender(OR 2.91, CI 1.23-6.91), Killip class 3 / 4 (OR 5.64, CI 2.27-14.03), Age ?62 y.o (OR 2.19, CI 1.00-4.83), White blood cell >12.000 (OR 2.12, CI0.95-4.73), Creatinine >1.5 (OR 2.17, CI 0.95-4.96), Body Mass Index ?25 (OR 1.71, CI 0.83-3.51), Multiple coronary lesion (OR 1.95, CI 0.83-4.54), Femoral access (OR 2.33, CI 0.77-7.01), and TPM implantation (OR3.21, CI 1.28-8.07). These variabels was converted into two type of scoringsystem. The INA-1 contains all of the variables, and INA-2 minus variablesrelated to interventional result and procedures.Conclusion Indonesia bleeding score quantifies risk for in-hospital bleedingevent in STEMI patients underwent PPCI, which enhances baseline riskassessment for STEMI care.
TNF ?, LVH, Prehypertension, Abdominal obesity Frans Wantania; Lucia Panda; Reggy L. Lefrandt
Jurnal Kardiologi Indonesia Vol. 34, No. 4 Oktober - Desember 2013
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v34i4.381

Abstract

Introduction : Left Ventricular Hypertrophy (LVH) as an independentpredictor of mortality may develop in non diabetes obese. There’s a roleof inflammation because adipose tissue release the proinflammatory cytokinessuch as TNF ?. It is important to prove this inflammatory state andits impact to the healthy obese for preventing cardiovascular events in thefuture. Purpose of this study is to investigate correlation of TNF ? levelwith LVH and Prehypertension in non diabetes abdominal obesity.Methods : Eighty-two male abdominal obesity and non abdominal obesitysubjects with no history of diabetes were recruited in this cross-sectionalstudy. Tumor Necrosis Factor Alpha level were measured with radioimmunoassay,blood pressure measurement was taken 2 times. Left VentricularMass Index(LVMI) were evaluated by M-Mode and two dimensionechocardiogram and value above 115 g/m2 are indicative of LVH.Result : TNFa alpha level is higher in abdominal obesity group as compareto non abdominal obesity (0,7133+0,2072 pg/ml vs 2,395+1,5371 pg/ml,p<0,001). Most of obese subjects developed prehypertension. Subjectswith prehypertension showed higher plasma TNF alpha level as compare tosubject with normal blood pressure (2,83+1,649 pg/ml vs 1,38 + 0,3245pg/ml, p<0,001). We also found the LVH in 30 (60%) of abdominal obesitysubjects. Obese subject had larger LVMI than non obese (138,427+47,461g/m2 vs 90,188+16,06 g/m2, p<0,001), and correlates positively to plasmaTNF alpha level (r=0,727, p,<0,001).Conclusion : High level of plasma TNF alpha is associated with left ventricularhypertrophy and prehypertension in non diabetes male abdominalobesity.
Pencabutan Kabel Pacu Alat Elektronik Kardiak Implan I Made Putra Swi Antara; Yoga Yuniadi
Jurnal Kardiologi Indonesia Vol. 34, No. 4 Oktober - Desember 2013
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v34i4.382

Abstract

As more people are living longer with more significant cardiac disease,permanent pacemakers (PPMs) and implantable cardioverter-defibrillators(ICDs) are being inserted more frequently each year. Beginning early in the21st century, there has also been an expansion in the indications for cardiacimplantable electronic devices (CIED, a term which includes PPMs andICDs), and device therapy has become more complex, frequently involvingmultiple leads per patient. In turn, there will be more occasion where thelead removal for these CIED will be necessary.A 6 y.o. patient was incidentally found to have a fractured pacemaker leadduring during routine x-ray for his respiratory tract infection. The pacemakerwas inserted 5 years ago, indicated for the permanent total atrioventricularblock developed after total correction surgery in Tetralogy of Fallot. Thelead fracture was thought to be caused by a phenomenon known as thesubclavian crush syndrome. A transvenous lead extraction in this patientwas only partially successful, leading to a surgical removal of the remaininglead. A new permanent pacemaker along with a new lead in the apexwas successfully inserted before the surgery.There are different levels of recommendations on whether a lead shouldbe extracted or left behind. And in times where removal was needed,new specialized tool and techniques have developed in the last decade forthe safe and successful retrieval of implanted pacemaker leads.
Pedoman Tatalaksana Dislipidemia PERKI 2013 Erwinanto E; Anwar santoso; Johannes NE Putranto; Pradana Tedjasukmana; Rurus Suryawan; Sodiqur Rifqi; Sutomo Kasiman
Jurnal Kardiologi Indonesia Vol. 34, No. 4 Oktober - Desember 2013
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v34i4.385

Abstract

Pedoman tatalaksana ini merupakan pedomantatalaksana dislipidemia pertama yang dibuat olehPERKI. Tujuan pembuatan pedoman tatalaksana iniadalah untuk membantu dokter membuat keputusandalam praktek sehari-hari. Pedoman inimenyarikandan mengevaluasi bukti-bukti yang ada ketikapedoman tatalaksana ini dibuat. Isi dari pedomantatalaksana ini mengacu terutama pada pedomantatalaksana dislipidemia ESC/EAS tahun 2011 sertaberbagai hasil penelitian lainnya. Keputusan akhirtentang terapi individual merupakan tanggung jawabdari dokter yang menangani pasien.
Secretory Phospholipase A2 Tipe Ii (Spla Ii) pada Penyakit Kardiovaskuler Djanggan Sargowo
Jurnal Kardiologi Indonesia Vol. 34, No. 4 Oktober - Desember 2013
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v34i4.386

Abstract

Reaksi inflamasi berperan dalam beberapa pathogenesis kondisi kardiovaskuler seperti atherosklerosis dan kerusakan iskemikpada infark miokard akut (IMA). Di antara mediator-mediator yang terlibat dalam inflamasi tersebut adalah enzim secretoryphospholipase A2 tipe II (sPLA2-II). Meskipun beberapa sel memang memproduksi sPLA2-II, namun sintesis oleh sel-sel tertentuseperti hepatosit, adalah khas sebagai reaktan fase akut. Literatur terbaru menyatakan banyaknya peran dari sPLA2-II dalampenyakit kardiovaskuler. Dalam tulisan berikut, akan mendiskusikan peran sPLA2-II dalam berbagai model atherosklerosisatau IMA, baik in vitro maupun in vivo, termasuk perspektif terapeutik dari sPLA2-II inhibitor. Disimpulkan bahwa sPLA2-IImerupakan mediator inflamasi yang penting dalam penyakit kardiovaskuler.
MRI Kardiak untuk Gagal Jantung akibat Kardiomiopati Sony Hilal Wicaksono; Donny Setyawan Syamsul; Citra Primasari; Aprivita Gayatri; Asmoko Resta Permana
Jurnal Kardiologi Indonesia Vol. 34, No. 4 Oktober - Desember 2013
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v34i4.387

Abstract

Kardiomiopati (KM) merupakan penyakit miokardium dengan karakteristik gangguan yang nyata pada morfologi, elektrofisiologi dan fungsi jantung.1 Definisilain menyebutkan bahwa KM adalah kelainan miokardium dengan abnormalitas pada struktur dan fungsi otot jantung, tanpa adanya penyakit jantung koroner, hipertensi, penyakit jantung katup ataupun kongenital yang melatarbelakanginya.Kardiomiopati dapat diklasifikasikan dalam dua kelompok besar yaitu KM primer dan KM sekunder. KM primer merupakankardiomiopati yang etiologinyatidak diketahui sedangkan kardiomiopati sekunder merupakan kardiomiopati yang diketahui etiologinya atau terkait kelainan sistemik maupun kelainanmiokardium khusus lainnya.2 Penegakan diagnosis KM dan klasifikasinyadidasarkan pada penilaian morfologi dan fungsi jantung.3 Penetapan diagnosis KM primer dilakukan dengan mengeksklusi penyakit/kelainan jantung yanglain.4 Seiring pengamatan klinis, perbedaan antara KM primer dan sekunder akan menjadi semakin jelas, karena ditemukannya etiologi pada kasusyang sebelumnya dianggap merupakan kelainan idiopatik.2
Ekokardiografi Transtorakal pada Deteksi Awal Gangguan Fungsi Katup Mitral Prostetik Hasanah Mumpuni; Amiliana M Soesanto
Jurnal Kardiologi Indonesia Vol. 34, No. 4 Oktober - Desember 2013
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v34i4.388

Abstract

Pemeriksaan ekokardiografi transtorakal (TTE)merupakan cara yang masih diandalkandalam skrening gangguan fungsi katup mitralprostetik (prosthetic mitral valve – PMV),karena ekokardiografi transesopagus (TEE) tidakdapat dikerjaan secara rutin. Tetapi adanya gambaranacoustic shadow sangat mengganggu pada deteksidisfungsi PMV dengan pemeriksaan TTE terutamaadanya regurgitasi.
Sindrom Bradi-Takiaritmia Yoga Yuniadi
Jurnal Kardiologi Indonesia Vol. 34, No. 4 Oktober - Desember 2013
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v34i4.389

Abstract

Seorang perempuan usia 67 tahun datang ke poli Aritmia dengan keluhan sering lemas dan berdebar. Tidak ada riwayat pingsan atau nyeri dada. Pemeriksaan fisik dalam batas normal. Pemeriksaan laboratorium tidak menunjukkan kelainan yangbermakna. Pemeriksaan holter 24 jam menunjukkan gambaran di bawah ini (Gambar 1).
Mitra Clip: Looking at its chance in developing country Yoga Yuniadi
Jurnal Kardiologi Indonesia Vol. 35, No. 2 April - Juni 2014
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v35i2.393

Abstract

Looking at developed countries data on valvular heart diseases, mitral regurgitationis one of the most commonly encountered valvular lesions. Moderate to severe regurgitation present in up to 30% of patients with various clinical subsets. Mitral regurgitation severity has been positively correlated with the subsequent development of heart failure and death.1-4The 2008 ACC/AHA guidelines describe three types of MV operations: (i) MV repair; (ii) MV replacement with chordal preservation; and (iii) MV replacement with removal of the mitral apparatus. The ACC/AHA guidelines support MV surgery for patients with severe (3– 4+) MR who are symptomatic with preserved LV size and function, asymptomatic with LV dysfunction or increased LV size, who have recent onset atrial fibrillation or evidence of pulmonary hypertension, or in symptomatic patients with severe LV dysfunction (LVEF ?30%) despite optimal medical therapy.Currently, a new percutaneous approach for treating mitral regurgitation (so called MitraClip) which involves mechanical edge-to-edge coaptation of the mitral leaflets has been developed. The device mechanism is analogous to the surgical Alfieri technique.MitraClip (Abbott Vascular, Abbott Park, Illinois, USA; formerly manufactured by EvalveInc, Menlo Park, California, USA) has been approved by FDA last year.5Since 2008 almost 4000MitraClip have been implanted all over the world (Figure 1).6Overall, the procedure has proven to be safe with exceedingly low rates of fatal or life-threatening complications. Additionally, significant improvements in functional capacity and quality of life have been reported following MitraClip implantation. However, apart from these encouraging results, open questions remain to be addressed, particularly about long term durability and clinical efficacy, and the selection of the most appropriate candidates for MitraClip implantation. As the experience with this procedure continues to expand, larger studies are expected that will help to further define the role of the MitraClip procedure among established therapies.6Patient selection is utmost important to gain procedural success. Two main criteria of Endovascular Valve Edge-to-Edge Repair Study (EVEREST) for patient selection are clinical and anatomical criteria. Clinical criteria comprise of moderate-to-severe (3+) and severe (4+) mitral regurgitation, meeting class I indications for intervention (MVR or mitral valve replacement) by the ACC/AHA or ESC guidelines, mitral reguritationaetiology limited to degenerative or functional, non-rheumatic or -endocarditic origin, andhigh surgical risk by EuroSCORE or STS scores. Anatomical criteria comprise of mitral regurgitation originating from the central 2?3 of the valve, mitral orifice area ?4 cm2, meeting criteria for degenerative mitral regurgitation (i.e. flail gap <10 mm, flail width <15 mm), meeting criteria for functional mitral regurgitation (i.e. coaptation depth ? 11 mm, coaptation length ? 2 mm).7, 8
Preoperative and predischarge predictors for persistent pulmonary hypertension after mitral valve surgery in patients with chronic organic mitral regurgitation Rina Ariani; Indriwanto Sakidjan; Budhi Setianto
Jurnal Kardiologi Indonesia Vol. 35, No. 2 April - Juni 2014
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v35i2.394

Abstract

Objectives. This study sought to evaluate the prevalence of pulmonary hypertension after mitral valve surgery ini patients with chronic organic mitral regurgitation and to determine preoperative and predischarge predictors for persistent pulmonary hypertension after surgeryMethods. This is a cohort retrospective study involving subjects with chronic organic mitral regurgitation with preoperative systolic PA pressure > 50 mmHg undergoing surgery. Demographic and echocardiography datas were collected prior to surgery, predischarge, and follow up datas were evaluated after minimal 6 months duration. Subjects were then devided into groups based on existence of persistent pulmonary hypertension after follow up. Bivariate and multivariate analysis was done to determine contributing factors.Results.There were 92 subjects with dominant mitral regurgitation included in this study with median age 40 (range 17-68) years with slight female predominance (55%). Persistent pulmonary hypertension was observed in 23 subjects (25%) predischarge and in 20 subjects (20.7%) after mean follow up of 11 + 5.5 months. Bivariate analysis revealed preoperative TAPSE, underlying etiology, severity of pulmonary hypertension preoperatively, postoperative atrial fibrilation, mean mitral valve gradient predischarge, and the presence of residual pulmonary hypertension predischarge were related with persistent pulmonary hypertension. From multivariate analysis, post operative atrial fibrillation [OR 7.3 (CI 95% 1.64-33.33, p=0.09)], mean mitral valve gradient predischarge [OR 1.67 (CI 95% 1,3-2.7, p=0.038)], and preoperative TAPSE [OR 0.143 (CI 95% 0.03-0.70, p=0.017)] were independent predictors for persistent pulmonary hypertension after mitral valve surgery.Conclusion. Persistent pulmonary hypertension was observed in 20.7% subjects after mitral valve surgery. Preoperative TAPSE, post operative atrial fibrillation, and predischarge mean mitral valve gradient were independent predictors.

Page 47 of 72 | Total Record : 712

 45   46   47   48   49 

Filter by Year

2002 2025


Reset
Filter By Issues
All Issue Vol 46 No 4 (2025): October - December, 2025 Vol 46 No 3 (2025): July - September, 2025 Vol 46 No 2 (2025): April - June, 2025 Vol 46 No 1 (2025): January - March, 2025 Vol 45 No Suppl_A (2024): Vol 45 No Suppl_A (2024): Abstracts of the 6th Indonesian Intensive & Acut Vol 45 No 4 (2024): Online First - Indonesian Journal of Cardiology April-June 2021 Vol 45 No 3 (2024): July - September, 2024 Vol 45 No 2 (2024): April - June, 2024 Vol 45 No 1 (2024): January - March, 2024 Vol 45 No Suppl_C (2024): Abstracts of the 33rd Annual Scientific Meeting of the Indonesian Heart As Vol 45 No Suppl_B (2024): Abstracts of the 11th Annual Scientific Meeting of the Indonesian Heart Rh Vol 44 No 4 (2023): Indonesian Journal of Cardiology: October - December 2023 Vol 44 No 3 (2023): Indonesian Journal of Cardiology: July - September 2023 Vol 44 No 2 (2023): Indonesian Journal of Cardiology: April - June 2023 Vol 44 No 1 (2023): Indonesian Journal of Cardiology: January - March 2023 Vol 44 No Suppl_A (2023): Abstracts of the 32nd Annual Scientific Meeting of the Indonesian Heart As Vol 44 No Suppl_B (2023): Abstracts of the 10th Annual Scientific Meeting of the Indonesian Heart Rh Vol 43 No 4 (2022): Indonesian Journal of Cardiology: October - December 2022 Vol 43 No 3 (2022): Indonesian Journal of Cardiology: July - September 2022 Vol 43 No 2 (2022): Indonesian Journal of Cardiology: April - June 2022 Vol 43 No Suppl_B (2022): Abstracts of the 6th InaPrevent (2022) Vol 43 No 1 (2022): Indonesian Journal of Cardiology: January - March 2022 Vol 43 No Suppl_C (2022): Abstracts of the 31st Annual Scientific Meeting of the Indonesian Heart As Vol 43 No Suppl_D (2022): Abstracts of the 9th Annual Scientific Meeting of the Indonesian Heart Rhy Vol 43 No Supplement (2022): Abstracts of the 5th Indonesian Intensive and Acute Cardiovascular Care Vol 42 No 4 (2021): Indonesian Journal of Cardiology: October - December 2021 Vol 42 No 3 (2021): Indonesian Journal of Cardiology: July - September 2021 Vol 42 No 2 (2021): Indonesian Journal of Cardiology: April - June 2021 Vol 42 No 1 (2021): Indonesian Journal of Cardiology: January - March 2021 Vol 42 No Supplement (2021): Abstracts of the 5th InaPrevent in Conjunction with the 1st InTension S Vol 42 No Supplement (2021): Abstracts of the 13th Indonesian Society of Interventional Cardiology A Vol 42 No Supplement (2021): Abstracts of the 8th Annual Scientific Meeting of the Indonesian Heart Vol 41 No 4 (2020): Indonesian Journal of Cardiology: October - December 2020 Vol 41 No 3 (2020): Indonesian Journal of Cardiology: July - September 2020 Vol 41 No 2 (2020): Indonesian Journal of Cardiology: April - June 2020 Vol 41 No 1 (2020): Indonesian Journal of Cardiology: Januari - Maret 2020 Vol 41 No Suppl_A (2020): Abstracts of the 29th Annual Scientific Meeting of the Indonesian Heart As Vol 41 No Suppl_B (2020): Abstracts of the 12th Indonesian Society of Interventional Cardiology Annu Vol 40 No 4 (2019): Indonesian Journal of Cardiology: October-December 2019 Vol 40 No 3 (2019): Indonesian Journal of Cardiology: July-September 2019 Vol 40 No 2 (2019): Indonesian Journal of Cardiology: April-June 2019 Vol 40 No 1 (2019): Indonesian Journal of Cardiology: January-March 2019 Vol 39 No 4 (2018): Indonesian Journal of Cardiology: October-December 2018 Vol 39 No 3 (2018): Indonesian Journal of Cardiology: July-September 2018 Vol 39 No 2 (2018): Indonesian Journal of Cardiology: April-June 2018 Vol 39 No 1 (2018): January - March 2018 Vol 39 No 1 (2018): January - March 2018 Vol 39 No Suppl_A (2018): Indonesian Journal of Cardiology Supplement_A Vol 39 No Suppl_B (2018): Indonesian Journal of Cardiology Supplement_B Vol 39 No Suppl_B (2018): Indonesian Journal of Cardiology Supplement_B Vol 39 No Suppl_A (2018): Indonesian Journal of Cardiology Supplement_A Vol 38 No 4 (2017): October - December 2017 Vol 38 No 4 (2017): October - December 2017 Vol 38 No 3 (2017): July - September 2017 Vol 38 No 3 (2017): July - September 2017 Vol. 38, No. 2 April-June 2017 Vol. 38, No. 2 April-June 2017 Vol. 38, No. 1 Januari-Maret 2017 Vol. 37, No. 4 Oktober - Desember 2016 Vol. 37, No. 3 Juli - September 2016 Vol. 37, No. 2 April - Juni 2016 Vol. 37, No. 1 Januari - Maret 2016 Vol. 36, No. 4 Oktober - Desember 2015 Vol. 36, No. 3 Juli - September 2015 Vol. 36, No. 2 April - Juni 2015 Vol. 36, No. 1 Januari - Maret 2015 Vol. 35, No. 4 Oktober - Desember 2014 Vol. 35, No. 3 Juli - September 2014 Vol. 35, No. 2 April - Juni 2014 Vol. 35, No. 1 Januari - Maret 2014 Vol. 34, No. 4 Oktober - Desember 2013 Vol. 34, No. 3 Juli - September 2013 Vol. 34, No. 2 April - Juni 2013 Vol. 34, No. 1 Januari - Maret 2013 Vol. 33, No. 4 Oktober - Desember 2012 Vol. 33, No. 3 Juli - September 2012 Vol. 33, No. 2 April - Juni 2012 Vol. 33, No. 1 Januari - Maret 2012 Vol. 32, No. 4 Oktober - Desember 2011 Vol. 32, No. 3 Juli - September 2011 Vol. 32, No. 2 April - Juni 2011 Vol. 32, No. 1 Januari - Maret 2011 Vol. 31, No. 3 September - Desember 2010 Vol. 31, No. 2 Mei - Agustus 2010 Vol. 31, No. 1 Januari - April 2010 Vol. 30, No. 3 September - Desember 2009 Vol. 30, No. 2 Mei - Agustus 2009 Vol. 30, No. 1 Januari - April 2009 Vol. 29, No. 3 September - Desember 2008 Vol. 29, No. 2 Mei - Agustus 2008 Vol. 29, No. 1 Januari - April 2008 Vol. 28, No. 6 November 2007 Vol. 28, No. 5 September 2007 Vol. 28, No. 4 Juli 2007 Vol. 28, No. 3 Mei 2007 Vol. 28, No. 2 Maret 2007 Vol. 28, No. 1 Januari 2007 Vol. 26, No. 1 Januari - Maret 2002 More Issue